Prima BioMed Ltd (PBMD) Shares are Down -3.98%

Prima BioMed Ltd (PBMD) : During the past 4 weeks, traders have been relatively bearish on Prima BioMed Ltd (PBMD), hence the stock is down -8.5% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.95% relative to the S&P 500. The 4-week change in the price of the stock is -8.15% and the stock has fallen -3.98% in the past 1 week.

Prima Biomed Ltd. has dropped 16.34% during the last 3-month period . Year-to-Date the stock performance stands at -25.88%. The stock has recorded a 20-day Moving Average of 4.81% and the 50-Day Moving Average is 9.88%.


Prima BioMed Ltd (NASDAQ:PBMD): The stock opened at $0.85 on Friday but the bulls could not build on the opening and the stock topped out at $0.86 for the day. The stock traded down to $0.83 during the day, due to lack of any buying support eventually closed down at $0.85 with a loss of -1.09% for the day. The stock had closed at $0.85 on the previous day. The total traded volume was 44,944 shares.

Also, Maxim Group initiates coverage on Prima BioMed Ltd (NASDAQ:PBMD) In a research note issued to the investors, the brokerage major announces price-target of $4 per share.The shares have been rated Buy. The rating by the firm was issued on April 18, 2016.

Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Companys main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response. The Companys product is a T cell immunostimulatory factor (APC activator), IMP321, for cancer chemoimmunotherapy, which has completed Phase II trials. In addition, it has developed infrastructure for a cell-based therapy manufacturing platform and taken CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. The Companys other products include IMP731 for autoimmune disease, and IMP701 for cancer and chronic infectious disease.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.